Back to News
Market Impact: 0.35
Glaukos' Epioxa Shows Durable Benefits At Three Years In Keratoconus Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Glaukos reported positive topline results from the long-term Phase 3 extension study GLK-202-03 evaluating Epioxa’s durability, visual outcomes and safety. The provided article text contains no numerical results or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
GKOS0.65
More News
- Glaukos: The Second J-Code Rewrites The Risk Math
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- Guitar Center is dropping its ban on playing ‘Stairway to Heaven.’ It’s part of the CEO’s big turnaround plan
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit